Ypsomed Holding AG · SIX:YPSN
Ypsomed — H1 2016/17 Earnings Presentation
37 slides from Ypsomed's earnings presentation, Nov 3, 2016
Slide 1: Ypsomed – Presentation of 2016/17 Semiannual Results
Ypsomed – Presentation of 2016/17 Semiannual Results Zürich, 3 November 2016
Slide 2: Important notice
Important notice The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herei
Slide 3: Agenda
Agenda 1. Introduction 2. Operational business 3. Financials 4. Outlook 5. Questions and answers 3 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 4: Convincing semiannual results 2016/17
Convincing semiannual results 2016/17 Increase in net sales by CHF 27.6 million to CHF 185.4 million (+17.5%) In comparison with the period the previous year, EBIT increased by 45.0% to CHF 28.1 million (previous year CHF 19.4 million) EBIT margin is 15.2% (previous year 12.3%) Earnings per
Slide 5: Ypsomed continues on its path of growth
Ypsomed continues on its path of growth 5 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 6: Growth above expectations
Growth above expectations 6 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 7: EBIT margin above 15%
EBIT margin above 15% 7 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 8: Strong growth in profitability
Strong growth in profitability 8 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 9: Changes in segmentation
Changes in segmentation Net sales will be disclosed according to the sales structure Operating profit will be disclosed on group level 9 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 10: Agenda
Agenda 1. Introduction 2. Operational business 3. Financials 4. Outlook 5. Questions and answers 10 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 11: Injection systems
Injection systems 11 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 12: Growth through GLP-1 pens and contract manufacturing
Growth through GLP-1 pens and contract manufacturing as well as execution of a substantial number of projects 12 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 13: Growth through GLP-1 pens and contract manufacturing
Growth through GLP-1 pens and contract manufacturing as well as execution of a substantial number of projects 13 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 14: Current growth drivers in YDS
Current growth drivers in YDS 14 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 15: Projects are converted to commercial pen supplies in the mid-term
Projects are converted to commercial pen supplies in the mid-term 15 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 16: Ongoing development of our platforms
Ongoing development of our platforms 16 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 17: Extension of our production infrastructure
Extension of our production infrastructure 17 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 18: Planned expansion of production capacities
Planned expansion of production capacities 18 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 19: Diabetes Care
Diabetes Care 19 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 20: Accelerated growth following currency-related stagnation
Accelerated growth following currency-related stagnation 20 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 21: Accelerated growth following currency-related stagnation
Accelerated growth following currency-related stagnation 21 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 22: DiaExpert – growth exceeds expectations
DiaExpert – growth exceeds expectations 22 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 23: mylife OmniPod – unabated growth trend
mylife™ OmniPod® – unabated growth trend 23 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 24: mylife YpsoPump – cooperation with Novo Nordisk
mylife™ YpsoPump® – cooperation with Novo Nordisk 24 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 25: mylife YpsoPump – overview of system components
mylife™ YpsoPump® – overview of system components 25 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 26: mylife YpsoPump – launch status
mylife™ YpsoPump® – launch status Controlled market launch in the Netherlands and United Kingdom Studies are currently being conducted in Germany – no special occurrences to-date Market launch in Germany and Czechia in November 2016 Italy, Norway, Sweden and Denmark have already started subm
Slide 27: Agenda
Agenda 1. Introduction 2. Operational business 3. Financials 4. Outlook 5. Questions and answers 27 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 28: EBIT increased by 45%
EBIT increased by 45% 28 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 29: Net profit margin above 10%
Net profit margin above 10% 29 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 30: High cash level allows flexibility in the operative business
High cash level allows flexibility in the operative business 30 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 31: Equity ratio enhanced
Equity ratio enhanced 31 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 32: Positive free cash flow supports growth
Positive free cash flow supports growth 32 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 33: Agenda
Agenda 1. Introduction 2. Operational business 3. Financials 4. Outlook 5. Questions and answers 33 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 34: Outlook – 2016/17 financial year
Outlook – 2016/17 financial year We increase the outlook for growth in net sales to around 15% The operating result of around CHF 55 million is confirmed 34 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 35: Important dates
Important dates Presentation of 2016/17 annual results in Burgdorf 24 Mai 2017 Annual General Meeting in Burgdorf 28 June 2017 35 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 36: Agenda
Agenda 1. Introduction 2. Operational business 3. Financials 4. Outlook 5. Questions and answers 36 | Ypsomed Holding AG | Presentation semiannual results 2016/17
Slide 37: Questions & answers
Questions & answers